Glecaprevir-Pibrentasvir

Generic Name: Glecaprevir/Pibrentasvir

Brand Names: Mavyret

Mavyret is an 8-week pan-genotypic hepatitis C cure for most treatment-naive patients without cirrhosis.

AntiviralHepatitis

What It's Used For

Glecaprevir-pibrentasvir is prescribed for:

Chronic hepatitis C (all genotypes)
Treatment-naive patients (8 weeks)
Treatment-experienced patients
Gastrointestinal liver disease

Shortest treatment duration for eligible patients.

Side Effects

Common side effects:

Headache
Fatigue
Nausea
Diarrhea

Serious side effects:

Hepatitis B reactivation
ALT elevations in some patients

Additional Information

What is Glecaprevir-Pibrentasvir?

Mavyret offers the shortest hepatitis C treatment course - just 8 weeks for most patients.

Who Qualifies for 8 Weeks

Treatment-naive patients without cirrhosis across all genotypes can be cured in 8 weeks.

Kidney Safety

Safe in severe kidney disease, unlike some other HCV treatments.

Learn more at MedlinePlus.

Related Health Conditions

This medication is commonly used to treat or manage the following conditions:

Cirrhosis

Cirrhosis is irreversible, late-stage liver disease where scar tissue replaces healthy tissue, impairing its vital functions like filtering toxins and often caused by alcohol abuse or hepatitis.

Learn More

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.

Loading questions...

Ask Dr. Zimmer

Have questions about Glecaprevir-Pibrentasvir? Get expert answers from Dr. Zimmer.

Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.

Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.

Menu